VitiligoTARGET-DERM+NCT07748169
An Observational Study of Patients With Dermatologic Disease
An observational study of Vitiligo and Atopic Dermatitis, run by Target PharmaSolutions, Inc. at 1 site in United States.
Trial summary
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Vitiligo, Atopic Dermatitis, Alopecia Areata
- How many people
- 2,000,000 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2026to 3 Aug 2041
- How long will I take part?
- 15 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 2,000,000
Who may be able to join
- Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
- Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.
Who cannot join
- Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Greenwich Village Dermatology
New York, New York, 10012
Jasmina Jeter, 212-385-3700, jjeter@thedermspecs.com
Andrew Peranteau
About this study
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Read the detailed description
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them. TARGET-DERM+ is designed to develop a large, robust database of real-world data regarding the natural history, management, and health outcomes related to the care of DD of diverse etiologies and practice settings. The study is also designed to establish learning health networks focused on quality of care for patients with DD.
- Keywords
- Dermatologic Disease, DERM+
- Medical subject headings
- Vitiligo, Dermatitis, Atopic, Alopecia Areata, Hidradenitis Suppurativa, Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Disease Cohort | Adult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface. | |
| Engaged Cohort | Adult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions. * Informed consent is required for all participants in an Engaged Cohort. * Willing to complete required Engaged Cohort activities. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease
The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD
Measured: 15 years
To characterize the natural history of disease in patients with dermatologic disease from various etiologies
A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.
Measured: 15 years
To establish learning health networks focused on quality of care for patients
Identify deficiencies and best practices in care of patients with DD.
- Evaluate outcomes from targeted learning content in the management of patients with DD.
Measured: 15 years
Secondary outcomes (2)
To evaluate provider management practices in the treatment of patients with DD
Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data.
Measured: 15 years
To evaluate longitudinal and patient reported outcomes in DD
Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health.
Measured: 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study startSep 2026 (estimated)
- Primary completion3 Aug 2041 (estimated)
- Study completion3 Aug 2041 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VitiligoStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 2,000,000 participants (estimated)
- Target duration
- 15 Years
Sponsor and investigators
- Lead sponsor
- Target PharmaSolutions, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Laura Dalfonso, Study director, Pedestal Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07748169
- Sponsor's protocol ID
- TARGET-DERM+
- Acronym
- TARGET-DERM+
- Status last verified
- Sep 2026
- First submitted
- 21 Jul 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No